Journal profile · Medicine-Neurology (clinical)
Open Forum Infectious Diseases
ISSN 2328-8957 · Oxford University Press · UNITED STATES
Open Forum Infectious Diseases: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.38; fully open access; APC about USD 3,859; median 104 days to acceptance (132 articles, last 24 months); 3,336 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Open Forum Infectious Diseases is published by Oxford University Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Use and Resistance, Bacterial Identification and Susceptibility Testing and Respiratory viral infections research, together about 23.4% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Papers Sought by OFID OFID Authors OFID Audience OFID Subject Sections Interested in Submitting? IDSA Family of Journals Open Forum Infectious Diseases (OFID) is a fully open-access journal advancing the field of infectious diseases by publishing and promoting high-quality research that improves patient care and public health outcomes. Our goal is to foster collaboration among practitioners, researchers, and policymakers by providing a platform for the exchange of knowledge and ideas. The journal focuses on publishing innovative clinical and translational research, exploring the impact of the natural environment on infectious diseases, enhancing publication literacy among infectious diseases practitioners, and addressing global health challenges. See OFID’s full list of subject sections. OFID does not publish papers focused on non-infectious-diseases topics unless they are of inherent interest to the infectious diseases community (e.g., medical education papers that aren’t focused on infectious diseases but which have direct applicability to infectious diseases pedagogy). OFID also does not accept phase 1 clinical trials, which may be a better fit for our sister journal, The Journal of Infectious Diseases. Metrics Journal metrics Citation metrics Clarivate 2025 Impact Factor 3.8 2025 5 Year Impact Factor 3.5 Infectious Diseases (Rank by Impact Factor) 41/141 Immunology (Rank by Impact Factor) 81/183 Microbiology (Rank by Impact Factor) 76/167 2025 Cited Half-Life 4 years 2025 Immediacy Index 1 2025 Eigenfactor Score 0.03088 2025 Article Influence Score 1.269 Scopus 2025 CiteScore 5.9 Infectious Diseases (Rank by CiteScore) 90/361 Oncology (Rank by CiteScore) 116/428 2025 Source Normalized Impact per Paper (SNIP) 1.182 Readership 2025 Full Text Usage 3,122,641 About metrics Disclaimer Statements of fact and opinion in the articles in OFID are those of the respective authors and contributors and not of the Journal, Infectious Diseases Society of America, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, Infectious Diseases Society of America, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included. Papers Sought by OFID Innovative Clinical an
From the journal's Aims & Scope
Research area (LetPub): Medicine-Neurology (clinical)
Editor-in-chief Roger J. BedimoPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named Canada 5, Israel 4, United States 3, Switzerland 3, South Africa 3 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Use and ResistanceImmunology and Microbiology10.4%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology6.7%
- Respiratory viral infections researchMedicine6.3%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology6.1%
- Antimicrobial Resistance in StaphylococcusMedicine5.5%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.3%
- HIV/AIDS Research and InterventionsMedicine4.7%
- Pneumonia and Respiratory InfectionsMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Microbiology | Zone 3 |
| Minor | Immunology | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Microbiology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Microbiology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.38LetPub ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 41Publisher website ·
- CiteScore 2026-06
- 5.9LetPub ·
- CiteScore (publisher) 2025
- 90Publisher website ·
- SJR 2026-06
- 1.43LetPub ·
- SNIP 2026-06
- 1.18LetPub ·
- h-index
- 21LetPub ·
- h-index
- 103OpenAlex ·
- i10-index
- 3,164OpenAlex ·
- 2-year mean citedness
- 1.17OpenAlex ·
- Self-citation rate
- 5.3%LetPub ·
- Share of gold OA articles
- 99.9%LetPub ·
Volume
- Articles per year
- 706LetPub ·
- Downloads per year (publisher) 2025
- 3,122,641Publisher website ·
Articles by year OpenAlex count · 31,645 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 2,955 | 2,955 | 280 |
| 2025 | 3,336 | 3,336 | 2,764 |
| 2024 | 809 | 809 | 5,276 |
| 2023 | 3,143 | 3,143 | 8,822 |
| 2022 | 2,618 | 2,618 | 12,051 |
| 2021 | 2,316 | 2,316 | 13,962 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
104 daysMedian, submission to acceptance · P25–P75 77 days – 139 days
- Acceptance to online
- median 16 days (133 articles)
- Submission to online
- median 126 days
- Sample
- 132 articles with submission and acceptance dates (1,590 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 9 weeksLetPub ·
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,859 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,053 | — | — | |
| LetPub | USD 3,859 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Not considered
- phase 1 clinical trials
Article types accepted17
- brief reportManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- case reportManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- commentaryManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- correspondenceManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- editorialManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- editorial commentariesEditorial Commentaries 1200 N/A 2 20 N/ALength not stated
- id learning units for non-id specialistsID Learning Units for Non-ID Specialists 1500 Unstructured (150-word limit) 5 15 NoLength not stated
- id on the webID on the Web 750 Unstructured (150-word limit) 7 No limit NoLength not stated
- major articleMajor Article 3500 Structured (250-word limit) 5 50 NoLength not stated
- notes from the epidemic frontlinesNotes from the Epidemic Frontlines 1500 N/A No Limits 15 Strongly EncouragedLength not stated
- novel id casesNovel ID Cases 2000 Unstructured (150-word limit) 5 No limit NoLength not stated
- perspectiveManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- protocolTo ensure transparency for our peer reviewers and readers, authors reporting the findings of a Randomized Controlled Trial must submit or provide a link to (if …Length not stated
- reviewManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- review articleManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
- top questions in idTop Questions in ID 1500 Unstructured (150-word limit) 1 figure, 2 tables No limit NoLength not stated
- viewpointManuscripts may be submitted in the following categories. The editors reserve the right to change the category for consistency with OFID style. See the table fo…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, Open access, Peer review
- AI use Use of AI, chatbots and Large Language Models
OFID supports the World Association of Medical Editors’ recommendations on AI, chatbots, and scholarly manuscripts. If AI, a Large Language Model (LLM), or a similar tool is used in the development of a paper for OFID, the following is required: The AI/LLM cannot be credited as an author, as authorship requires that the author be accountable for the submitted/published work, and artificial intelli…
Source ↗Publisher website ·- Authorship Authorship
Authorship is limited to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. The Journal will contact all listed authors at the point of submission to confirm their role. For a detailed definition of authorship, please see …
Source ↗Publisher website ·- Conflicts of interest Disclosure of potential conflicts of interest
Authors The Journal requires all authors to disclose any potential conflict of interest at the point of submission. It is the responsibility of the corresponding author to ensure that conflicts of interest of all authors are declared to the Journal. A conflict of interest exists when the position, activities, or relationships of an individual, whether direct or indirect, financial or non-financial…
Source ↗Publisher website ·- Data availability Availability of data and materials
Where ethically feasible, the Journal strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. Authors are required to include a data availability statement in their paper. When data and software underlying the research article are available in an online source, authors should include a full citation in their reference list. Fo…
Source ↗Publisher website ·- Publication ethics Misconduct
Authors should observe high standards with respect to research integrity and publication ethics as set out by the Committee on Publication Ethics (COPE). Falsification or fabrication of data including inappropriate image manipulation, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of work are all unacceptable practices. Allegation…
Source ↗Publisher website ·- Open access Open access charge
Book review charge 3625 USD Society membership discount 20% Total 0 USD Charges are quoted based on the information provided. The Low and Middle Income Countries discount is applied prior to any other discount. Please note that these prices are subject to change. All stated charges are exclusive of any applicable value added tax, goods and services tax and any similar sales or excise taxes (Sales …
Source ↗Publisher website ·- Peer review Peer review process
Regular submissions The IDSA journals’ review process begins with an initial quality check to ensure that we have everything we need to send papers for peer review. Our journals are format free for new manuscripts. We do not require cover letters from authors; our submission system collects all information previously provided in cover letters, including an opportunity for authors to provide a brie…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2328-8957
- Latest issue on the website
- Volume 13, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Open Forum Infectious Diseases
What CAS zone is Open Forum Infectious Diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Open Forum Infectious Diseases is in Zone 4 of Medicine, and in Zone 3 of the minor category Microbiology / Immunology / Infectious Diseases. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Open Forum Infectious Diseases?
The latest impact factor listed by LetPub is 3.38; CiteScore 5.9, h-index 103.
How long does peer review take at Open Forum Infectious Diseases?
Based on the dates recorded on 132 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 104 days (interquartile range 77–139 days); authors report an average review time of about 9 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Open Forum Infectious Diseases based?
Of the 39 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are Canada (5), Israel (4) and United States (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Open Forum Infectious Diseases?
According to LetPub and DOAJ records, Open Forum Infectious Diseases is indexed in SCIE, Scopus and DOAJ.
Is Open Forum Infectious Diseases open access, and what is the APC?
Open Forum Infectious Diseases is a fully open-access journal. APC about USD 3,859.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .